| HOME | HELP | FEEDBACK | TABLE OF CONTENTS | ARCHIVE | SUBSCRIPTIONS |
|
|
|
||||||
|
||||||||
Letters to the Editor |
1 Department of Internal Medicine V, Hematology, Oncology and Rheumatology;
2 Department of Radiology;
3 Institute of Pathology, University of Heidelberg, Germany
Correspondence: Ute Hegenbart, MD, Amyloidosis Clinic, Department of Internal Medicine V, Hematology, Oncology and Rheumatology, University of Heidelberg, Im Neuenheimer Feld 410, D-69120 Heidelberg, Germany. Phone: international +49.6221568001. Fax: international +49.6221565721. E-mail:ute.hegenbart{at}med.uni-heidelberg.de
Key words: systemic AL amyloidosis, bone involvement, organ transplantation, magnetic resonance imaging, monoclonal gammopathy.
The definition of organ involvement in systemic AL amyloidosis has been recently published and a consensus conference has defined major criteria for 7 main organ systems.1 However, bone disease was not included in the list of affected organs and has not yet been systematically studied. It has been diagnosed rarely after emergency surgery of the spine.2,3
Using the Salmon and Durie classification4 patients with monoclonal gammopathy (MG) and osteolytic bone lesions in X-ray are diagnosed as multiple myeloma (MM) stage III. Differentiation between MG or MM as the underlying disease of AL amyloidosis might have significant therapeutic consequences.
Since 2004, we have systematically evaluated 330 patients with systemic AL amyloidosis admitted to our Amyloidosis Clinic for the underlying plasma cell disorder, organ involvement and the presence of bone lesions. Diagnosis of AL amyloidosis had been made using Congo-red staining and immunohistochemical confirmation of the light chain type of amyloid. Conventional bone X-ray was performed as usual in MM. Magnetic resonance imaging (MRI) of the whole body or regions of interest was also performed if osteolyses had been diagnosed or suspected in bone X-ray.5 Biopsy of the bone lesions had been confirmed in MRI was performed prior to starting chemotherapy. Patients gave their informed consent and the study was approved by the Ethics Committee of the University of Heidelberg.
Four patients with newly diagnosed systemic AL amyloidosis and osteolytic lesions due to amyloid deposits were identified. Two patients had involvement of the spine with spinal cord compression and underwent emergency surgery due to imminent paraplegia. The two other patients had large bone lesions in X-ray and MRI. Figure 1 shows X-ray (digital radiography) of the right proximal femur with osteolytic lesions in the diaphysis of the femur without sclerotic reaction and no alteration of the cortical bone. The corresponding coronal MR-Image (T2 STIR) delineates large areas of increased T2-intensity in the diaphysis of both femurs suggesting bone marrow infiltration by MM. In all 4 patients, biopsy material showed extensive depositions of amyloid in the bone, as well as monoclonal plasma cells and giant cells only at the margins. Patient characteristics and outcome are shown in Table 1.
|
|
Amyloid bone disease is rare and presents a challenge for diagnosis. Amyloidoma of the bone has only been reported in a few cases.7-9 Pambuccian described 3 new cases and 34 cases from the literature, and discussed solitary plasmocytoma with local amyloidosis as the cause of the bone destruction.7 The description of the histological picture is similar to that observed in our patients. However, at least one of the 3 patients in their report also had systemic organ involvement. Lipper and Lai describe bone amyloidoma patients with a long-term follow-up of up to 12 years without progression into advanced MM.8,9 Apart from MM, bone involvement has also been described in other hematologic malignancies, such as Hodgkin’s disease or non-Hodgkin’s lymphoma. However, biopsies in these cases showed tumor infiltrates in the bone similar to those in plasmocytoma. The histomorphological description in our patients implied that bone involvement was the result of local amyloid production and deposition because monoclonal plasma cells have only been detected at the margins of amyloid deposits. This is a characteristic phenomenon of local amyloidosis10 in which amyloid is deposited extracellularly at the site of the monoclonal light chain production. The amyloid in the bone might replace the normal bone structures and lead to destruction mimicking MM bone disease in X-ray and MRI.
Our study has two limitations. Whether diffuse amyloid bone marrow involvement might cause osteopenia cannot be answered and needs further investigation. Secondly, there is a risk that we have overlooked concomitant MM bone disease in patients 3 and 4 who presented approximately 20 bone lesions in MRI.
In our opinion, amyloid bone disease must be considered in patients with a monoclonal gammopathy and osteolytic bone lesions. In our institution, X-ray as well as MRI and bone biopsy for suspicious lesions are now included in the evaluation of newly diagnosed patients with systemic AL.
To summarize, amyloid involvement of the bone leading to osteolyses is rare. It might be the result of local amyloid production even in patients with systemic amyloidosis and can mimic lytic myeloma bone disease. Importantly, the diagnosis of advanced MM could mean the physician does not take into consideration cardiac11 or renal transplant12 as an effective treatment option prior to high-dose chemotherapy and blood progenitor cell transplantation in these patients.
References
| ||||||||||||||||||||||||||||||||||||||||||||||||
| HOME | HELP | FEEDBACK | TABLE OF CONTENTS | ARCHIVE | SUBSCRIPTIONS |
